REB

Brian Crane, CEO of Intero, a Berkshire Hathaway Affiliate, Named Among the 2024 Swanepoel Power 200 List

Retrieved on: 
Wednesday, January 10, 2024
Professional Services, Residential Building & Real Estate, Commercial Building & Real Estate, Finance, Construction & Property, REIT, Senior, REB, Berkshire Hathaway, Management

Intero, a Berkshire Hathaway affiliate and wholly owned subsidiary of HomeServices of America, Inc., is proud to announce its Chief Executive Officer, Brian Crane, has been named on the 2024 Swanepoel Power 200 (SP 200) list.

Key Points: 
  • Intero, a Berkshire Hathaway affiliate and wholly owned subsidiary of HomeServices of America, Inc., is proud to announce its Chief Executive Officer, Brian Crane, has been named on the 2024 Swanepoel Power 200 (SP 200) list.
  • The SP 200 ranks the most powerful and influential leaders and executives in the residential real estate brokerage industry.
  • Highly regarded within the real estate community, Brian is an industry veteran of more than three decades and one of the original founders of Intero.
  • He joins several other executives from across HomeServices’ brokerage and franchise companies who were also named to the SP 200 list, including Gino Blefari, CEO of HomeServices and chairman, Berkshire Hathaway HomeServices—and founder of Intero, who earned the #3 spot for 2024.

Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update

Retrieved on: 
Monday, November 13, 2023
Natural history, Clinical, REB, Oropharyngeal dysphagia, Dysphagia, Safety, Research, Dispute board, Principal investigator, IND, FIH, FDA, Oculopharyngeal muscular dystrophy, HIV disease progression rates, RNA, Pharmaceutical industry, Nursing, Medical imaging, Health insurance, Cryptocurrency, OPMD, Benitec Biopharma

Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.

Key Points: 
  • Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.
  • Total Revenues for the quarter ended September 30, 2023, were $0 compared to $0 for the quarter ended September 30, 2022.
  • Total Expenses for the quarter ended September 30, 2023 were $5.9 million compared to $4.6 million for the quarter ended September 30, 2022.
  • The loss from operations for the quarter ended September 30, 2023, was $5.9 million compared to a loss of $4.6 million for the quarter ended September 30, 2022.

Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, September 21, 2023
Oculopharyngeal muscular dystrophy, REB, Dysphagia, Natural history, Oropharyngeal dysphagia, Principal investigator, RNA-dependent RNA polymerase, Form 10-K, Research, RNA, Investigational New Drug, 52 Weeks Make A Year, HIV disease progression rates, FIH, Dispute board, FDA, Annual report, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Clinical, Food, Safety, Nursing, Pharmaceutical industry, Medical imaging, Health insurance, Cryptocurrency, Benitec Biopharma, OPMD

HAYWARD, Calif., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2023. The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2023, with the U.S. Securities and Exchange Commission.

Key Points: 
  • The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2023, with the U.S. Securities and Exchange Commission.
  • Dosing with BB-301: 1-day of BB-301 dosing to initiate participation in the Phase 1b/2a single-arm, open-label, sequential, dose-escalation cohort study.
  • In December 2022, Benitec began screening OPMD subjects at the lead clinical study site in the United States.
  • In January 2023, Benitec announced the enrollment of the first OPMD subject into the OPMD NH Study in the United States.

Benitec Biopharma Releases First Quarter 2023 Financial Results and Provides Operational Update

Retrieved on: 
Thursday, November 10, 2022
IND, CTA, Research, Principal investigator, Principal, Company, GMP, Child development stages, Institutional review board, GDPR, IRB, Disclosure, Benitec Biopharma, Dispute board, RNA, General Data Protection Regulation, U.S. Securities and Exchange Commission, Argonaute, Oculopharyngeal muscular dystrophy, Drug discovery, Dysphagia, Oropharyngeal dysphagia, HDL-Atherosclerosis Treatment Study, HIV disease progression rates, Achievement, United, Privacy, CEC, REB, Phenotype, GLOBE, FIH, Organization, Behavior, Muscle, NASDAQ, Safety, Union, Clinical, Validation, Animal, Natural history, Insurance, Pharmaceutical industry, Medicine, Medical imaging, Mineral wool, Medical device, OPMD, EU

Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma.

Key Points: 
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma.
  • In the Third Calendar Quarter 2022, Benitec submitted responses to the Central Ethics Committee (CEC) related to minor non-clinical queries.
  • BB-301 Phase 1b/2a Regulatory Updates:
    Investigational New Drug (IND) and Clinical Trial Application (CTA) filings are anticipated in the First Calendar Quarter 2023.
  • Total Revenues for the quarter ended September 30, 2022, were $0 compared to $0 for the quarter ended September 30, 2021.

Proactive news headlines including Archer Materials, Lake Resources, Anson Resources and Prescient Therapeutics

Retrieved on: 
Wednesday, September 14, 2022
Lithium, Graphite, Battery, Proactivity, FHE, OTC, Rare-earth element, CPH, Lead, ATC, ASX, Temperature, PTX, REB, Gold, Copper, Joint venture, MD Anderson Cancer Center, SureFire, Kachi, OTCQB, Cane Creek, Cobalt, SAS, Western Australian Government Railways, GLOBE, Water Corporation (Western Australia), Dispute board, LLC, Pancreatic cancer, NOX, Cancer, REE, University, Pharmaceutical industry, Mining

Click here

Key Points: 
  • Click here
    Surefire Resources NL (ASX:SRN) has confirmed the presence of lead and silver mineralisation through rock chip sampling at Mt Conspicuous prospect of the Kooline Project in Western Australia.
  • Click here
    Proactive is a unique tech-enabled platform providing companies globally with a comprehensive investor engagement solution across their business lifecycle.
  • Proactive has produced over 300,000 articles and 20,000 executive interviews since it was established in 2006.
  • For more information on how Proactive can help you make a difference, email us at [email protected]

Benitec Biopharma Releases Full Year 2022 Financial Results and Provides Operational Update

Retrieved on: 
Friday, September 2, 2022
Muscle, Safety, Research, Oculopharyngeal muscular dystrophy, Dispute board, Disclosure, Dysphagia, Principal investigator, U.S. Securities and Exchange Commission, GMP, GLOBE, Company, Patient, ICF, Patient Information Advisory Group, FIH, Institutional review board, REB, Phenotype, Argonaute, Annual report, Clinical, Trial of the century, Investigational New Drug, RNA, Form 10-K, NASDAQ, CTA, Oropharyngeal dysphagia, Animal, HDL-Atherosclerosis Treatment Study, Benitec Biopharma, Child development stages, Review, IRB, HIV disease progression rates, CEC, IND, Achievement, Natural history, Validation, Sales, Pharmaceutical industry, Medicine, Medical imaging, Mineral wool, Cryptocurrency, OPMD

HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec or the Company), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2022.

Key Points: 
  • HAYWARD, Calif., Sept. 02, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec or the Company), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year ended June 30, 2022.
  • The Company has filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma.
  • 52-weeks of post-dosing follow-up for conclusive evaluation of the primary and secondary endpoints of the Phase 1b/2a BB-301 treatment study.

TopLevel Launch: a Conceptually New Company with Experienced Brokers

Retrieved on: 
Friday, August 19, 2022
Emaar Properties, Dubai Properties, FirstGroup, Sale, Select Group, Inheritance, Communication, Marketing, Research, Outcomes First Group, REB, DAMAC Properties, Real estate, Public relations, Nakheel Properties

Dubai, United Arab Emirates--(Newsfile Corp. - August 19, 2022) - Today, representatives of TopLevel Real Estate Brokerage announced their official launch in the media.

Key Points: 
  • Dubai, United Arab Emirates--(Newsfile Corp. - August 19, 2022) - Today, representatives of TopLevel Real Estate Brokerage announced their official launch in the media.
  • Me and my husband transferred money to your company to pay for the apartment, and we were anxious at first.
  • We hope it will not be the last time we asked for your help", Yulia Zaporozhnikova, a client of TopLevel REB.
  • There is healthy communication between all units of TopLevel REB: founders, the management, sales, marketing and creative department, as well as IT security and other departments.

Benitec Biopharma Releases Q3 2022 Financial Results

Retrieved on: 
Monday, May 16, 2022
Phenotype, Company, Argonaute, Consultant, U.S. Securities and Exchange Commission, FIH, Principal investigator, GMP, Clinical, NH, Patient, Dysphagia, HDL-Atherosclerosis Treatment Study, File, Insurance, NASDAQ, Pi, ESB Business School, ICF, REB, Research, Natural history, OPMD, IND, Child development stages, Myopathy, Dispute board, CTA, RNA, Safety, Neurology, Charles River Laboratories, CEC, Muscle, Investigational New Drug, GLOBE, Pharmaceutical industry, Medicine, Medical imaging, Civil engineering

HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec or the Company), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022.

Key Points: 
  • HAYWARD, Calif., May 16, 2022 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (Benitec or the Company), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference ("ddRNAi") platform, today announced financial results for its Fiscal Year Q3 ended March 31, 2022.
  • The Company has filed its quarterly report on Form 10-Q for the quarter ended March 31, 2022, with the U.S. Securities and Exchange Commission.
  • Banks, M.D., Ph.D., Executive Chairman and Chief Executive Officer of Benitec Biopharma.
  • The Benitec team remains committed to initiating the clinical development program for BB-301 and improving the lives of patients suffering from OPMD.